As reported before, RPL23 is overexpressed at the mRNA level in higher-risk MDS patients, and elevated RPL23 expression is inversely associated with the apoptosis ratio in CD34+ BM cells, which might lead to disease progression and adverse prognosis. This evidence concerns the gene RPL23 and myelodysplastic syndrome.